Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Harrison CN. et al, (2023), J Clin Oncol
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
Mascarenhas J. et al, (2023), J Clin Oncol
Correction: Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.
Ryou H. et al, (2023), Leukemia
CHROMOTHRIPSIS AND LEUKEMIC TRANSFORMATION IN MPN
Brierley C. et al, (2023), EXPERIMENTAL HEMATOLOGY, 124, S65 - S65
Chromothripsis Orchestrates Leukemic Transformation in Blast Phase MPN through Targetable Amplification of DYRK1A
Brierley CK. et al, (2023), BLOOD, 142
Platelets Sequester Extracellular DNA, Capturing Tumour-Derived and Free Fetal DNA
Murphy L. et al, (2023), BLOOD, 142
Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia.
Rastogi N. et al, (2022), Leukemia
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.
Schnegg-Kaufmann AS. et al, (2022), Blood
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.
Ryou H. et al, (2022), Leukemia
CNL and aCML should be considered as single entity based on molecular profiles and outcomes.
Carreño-Tarragona G. et al, (2022), Blood Adv
Single-cell methods in myeloproliferative neoplasms - old questions, new technologies.
O'Sullivan JM. et al, (2022), Blood
MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood.
Zavidij O. et al, (2022), Clin Lymphoma Myeloma Leuk, 22 Suppl 2, S331 - S332
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN. et al, (2022), Future Oncol
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
Bueno C. et al, (2022), Blood, 140, 38 - 44
In utero origin of myelofibrosis presenting in adult monozygotic twins.
Sousos N. et al, (2022), Nat Med, 28, 1207 - 1211
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J. et al, (2022), Blood, 139, 2931 - 2941
Exploratory Analysis: Potential of pelabresib (CPI-0610), a bromodomain and extra-terminal domain inhibitor, as suggested by analysis of improvements in bone marrow histology and function in patients with myelofibrosis-preliminary data
Harrison C. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 27 - 28
Longitudinal and Individual Symptom Analyses of Momelotinib and Ruxolitinib-Treated Myelofibrosis Patients from SIMPLIFY-1
Mesa R. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 79 - 80